Crystal form E and crystal form F of canagliflozin and preparation method thereof

A crystal form and crystallization technology, applied in the field of hypoglycemic drugs, crystal form F and its preparation, and crystal form E of canagliflozin, which can solve the problem of poor crystallinity, poor fluidity and unstable baseline of crystal form C and other problems, to achieve good physical and chemical stability, improve drug solubility and dissolution rate, and control the process.

Active Publication Date: 2015-10-14
CRYSTAL PHARMATECH CO LTD
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology provides stable forms that have better properties than existing products such as CN102189622A or its modifications. These new types also provide finer and uniform sizes compared to other commercial lyophilization techniques used today. They may be easier to handle during manufacturing processes due to their small dimensions making them safer from handling issues at high temperatures. Additionally they make certain drugs less expensive because there's no needing an organic solvent like dimethyl sulfoxide when producing these medications. Overall this results in higher quality productivity rates while reducing costs associated with traditional pharmaceutical packaging materials.

Problems solved by technology

This patent discusses how certain drugs like cannabis or narcosistors called canagsuroside could cause side effect issues such as insulin resistance syndrome due to increased sugar absorption caused by ingested nutrients. To address these concerns, it suggests developing novel ways to improve the quality control of medications made through analysis techniques involving high performance liquid chromatography ("HPLC"), mass spectrometry," nuclear magnetic resonance spectroscopy."

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystal form E and crystal form F of canagliflozin and preparation method thereof
  • Crystal form E and crystal form F of canagliflozin and preparation method thereof
  • Crystal form E and crystal form F of canagliflozin and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089] Embodiment 1: Preparation of the crystal form E of canagliflozin

[0090] Dissolve 499.5 mg of canagliflozin powder in 13.25 mL of acetic acid: n-heptane = 1:3 (v:v) mixed system, and then quickly place it at -20°C and stir for 20 hours. The obtained solid is crystal Type E. Its XRPD pattern is shown in figure 1 , whose DSC diagram is shown in figure 2 , whose TGA diagram is shown in image 3 .

[0091] The corresponding values ​​of 2theta value and intensity of crystal form E in this embodiment are shown in Table 1:

[0092] Table 1 Corresponding value of 2theta value and intensity of crystal form E

[0093] 2theta

[0094] 38.89

Embodiment 2

[0095] Embodiment 2: Preparation of crystal form E of canagliflozin

[0096] Dissolve 19.6 mg of canagliflozin powder in 0.20 mL of acetic acid: n-heptane = 1:1 (v:v) mixed solvent, then quickly place it at -20°C and stir for 20 hours, and the obtained solid is crystal Type E.

[0097] The corresponding values ​​of 2theta value and relative intensity of crystal form E in this embodiment are shown in Table 2:

[0098] Table 2 Corresponding value of 2theta value and relative intensity of crystal form E

[0099] 2theta

Embodiment 3

[0100] Embodiment 3: Preparation of crystal form E of canagliflozin

[0101] Dissolve 21.1 mg of canagliflozin powder in 0.40 mL of acetic acid solvent, then add 0.50 mL of n-heptane and stir at room temperature for 5 days, and the obtained solid is Form E.

[0102] The 2theta value and intensity corresponding value of crystal form E in this embodiment are shown in Table 3:

[0103] Table 3 Corresponding values ​​of 2theta value and intensity of crystal form E

[0104] 2theta

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides two new crystal forms: a crystal form E and a crystal form F, of canagliflozin, and the preparation method thereof. The new crystal forms are greatly improved in form and particle size. The particles are fine in size and are dispersed uniformly, so that it is beneficial to improvement of medicine solubility and dissolution rate, thereby being beneficial to preparation development.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner CRYSTAL PHARMATECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products